Synaptics Appoints Ken Rizvi as Chief Financial Officer
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) today announced Ken Rizvi will join the […]
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Live webcast on Thursday, May 16that 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, […]
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and […]
Genasys Inc. Reports Fiscal Second Quarter 2024 Financial Results
Increased Scope in Puerto Rico Expands Opportunity to $75 million CROWS 16 Program Established SAN DIEGO, May 14, 2024 (GLOBE […]
Genasys Announces $15 Million Two-Year Term Loan Agreement
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in protective communications, today announced […]
Genasys Announces Expansion of Its Board of Directors
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in protective communications, today announced […]
OptimizeRx Reports First Quarter 2024 Financial Results
Q1 revenue of $19.7 million, increasing 51% year-over-year Q1 gross profit increased 64% year-over-year to $12.2 million with a gross margin […]
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a […]
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in […]
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed dosing in cohort one (low dose, 5.7×1014total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data […]
